The CHMP gives a positive opinion on, and recommends approval to Seagen’s (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
The CHMP gives a positive opinion on, and recommends approval to Seagen’s (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.